Role of c-MET in upper aerodigestive malignancies--from biology to novel therapies
- PMID: 16050800
- DOI: 10.1615/jenvpathtoxoncol.v24.i3.20
Role of c-MET in upper aerodigestive malignancies--from biology to novel therapies
Abstract
Overactivation and defective downregulation of receptor tyrosine kinase (RTK) pathways have been implicated in human carcinogenesis. RTKs represent an important class of anticancer novel therapeutic target. Some RTKs are known to be protooncogenes that can mediate signal transduction, alteration of reactive oxygen species (ROS), cellular proliferation, cell motility and migration, apoptosis, and survival. c-MET is a unique RTK that regulates a wide variety of cellular functions. c-MET has been shown to be overexpressed or mutated in a variety of human malignancies. Stimulation of c-MET via its natural ligand hepatocyte growth factor/ scatter factor (HGF/SF) leads to a plethora of biological and biochemical effects in the cell. Activation of c-MET signaling can lead to cell motility and scattering, angiogenesis, proliferation, branching morphogenesis, invasion, and eventual metastasis. This review summarizes the structure and functions of c-MET, with particular emphasis on its role in upper aerodigestive malignancies. The unique biological functions altered by c-MET and its mutations are discussed as well. Finally, c-MET, when mutated or overexpressed in malignant cells, serves as an important therapeutic target, and the most recent data with respect to its inhibition are also summarized in this review.
Similar articles
-
Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition.Cytokine Growth Factor Rev. 2002 Feb;13(1):41-59. doi: 10.1016/s1359-6101(01)00029-6. Cytokine Growth Factor Rev. 2002. PMID: 11750879 Review.
-
c-Met: structure, functions and potential for therapeutic inhibition.Cancer Metastasis Rev. 2003 Dec;22(4):309-25. doi: 10.1023/a:1023768811842. Cancer Metastasis Rev. 2003. PMID: 12884908 Review.
-
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.Cancer Res. 2003 Oct 1;63(19):6272-81. Cancer Res. 2003. PMID: 14559814
-
Targeting the MET gene for the treatment of non-small-cell lung cancer.Crit Rev Oncol Hematol. 2014 Feb;89(2):284-99. doi: 10.1016/j.critrevonc.2013.11.006. Epub 2013 Dec 1. Crit Rev Oncol Hematol. 2014. PMID: 24355409 Review.
-
Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.Clin Cancer Res. 2002 Feb;8(2):620-7. Clin Cancer Res. 2002. PMID: 11839685
Cited by
-
ROS and ROS-Mediated Cellular Signaling.Oxid Med Cell Longev. 2016;2016:4350965. doi: 10.1155/2016/4350965. Epub 2016 Feb 22. Oxid Med Cell Longev. 2016. PMID: 26998193 Free PMC article. Review.
-
The malignant pleural effusion as a model to investigate intratumoral heterogeneity in lung cancer.PLoS One. 2009 Jun 12;4(6):e5884. doi: 10.1371/journal.pone.0005884. PLoS One. 2009. PMID: 19536353 Free PMC article.
-
Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer.Br J Cancer. 2008 Sep 16;99(6):911-22. doi: 10.1038/sj.bjc.6604559. Br J Cancer. 2008. PMID: 19238632 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
